Does migraine with aura increase stroke risk?

Yes. Migraine with aura is associated with an increased risk of ischemic stroke, particularly in younger women. The absolute risk for an individual young woman remains relatively low, but the relative increase is consistent enough that migraine with aura is recognized as a stroke risk factor worth accounting for.

What is the difference between migraine with and without aura?

Aura refers to neurological symptoms, often visual disturbances like flashing lights or blind spots, that occur before or with the headache. The increased stroke association is specifically linked to migraine with aura, not migraine without aura, so knowing which type you have matters for risk assessment.

What makes the risk worse?

The stroke risk associated with migraine with aura compounds with other factors, particularly smoking and estrogen-containing contraception. Women with migraine with aura are generally advised to avoid smoking and estrogen-containing contraception, since these combine to raise stroke risk more than any one factor alone.

What should I do if I have migraine with aura?

Confirm whether your migraines include aura, ensure it is noted in your risk assessment, avoid smoking, and discuss non-estrogen contraception options if relevant. Manage other cardiovascular risk factors as well. The single migraine factor is most actionable in combination with these others.

How is cardiovascular risk calculated?

The ACC/AHA Pooled Cohort Equation estimates 10-year cardiovascular risk using age, sex, race, total cholesterol, HDL, systolic blood pressure, treatment status, diabetes, and smoking. A 10-year risk above 7.5 percent generally supports preventive statin therapy. Risk-enhancing factors including coronary artery calcium score, ApoB, high-sensitivity CRP, and adverse pregnancy history can modify the decision in borderline-risk patients. The calculator should be used as a starting point for shared decision-making, not a binary treatment threshold.

The Reproductive Clock

Migraine With Aura Is a Stroke Risk Factor in Women

Migraine with aura is associated with higher stroke risk, particularly in younger women. What the evidence shows and what it means for prevention.

Job Mogire, MD, FACP, FACC · Medically reviewed June 15, 2026

Migraine is treated as a headache problem, a matter of pain and management, and for most women that is the whole of it. But one specific form, migraine with aura, carries a cardiovascular signal that the headache framing obscures: it is associated with higher stroke risk, especially in younger women, and that risk compounds with factors a woman can actually do something about. Knowing which kind of migraine she has, and what it interacts with, is the point.

The Mechanism

To understand why migraine with aura carries a stroke signal, it helps to understand what aura actually is at the neurological level. Aura represents a wave of altered cortical activity known as cortical spreading depression: a slow-moving wave of neuronal depolarization followed by suppression that spreads across the cortex at roughly 3 to 5 millimeters per minute. This wave is what produces the characteristic visual phenomena, the flickering lights, the expanding arc of bright zigzags, the temporary blind spot, that most people recognize as aura. It can also produce sensory, motor, or language symptoms in some individuals, and in rarer forms it can cause motor weakness, which is classified separately as hemiplegic migraine.

The connection between this cortical event and stroke risk operates through several interlocking pathways that researchers are still characterizing. One involves the vascular effects of cortical spreading depression itself: the wave triggers changes in blood vessel tone and, in animal models, can induce brief reductions in cerebral blood flow that last for minutes. There is also evidence of heightened platelet activation in people with migraine with aura, which matters because platelet aggregation is central to clot formation. Levels of von Willebrand factor, a protein involved in platelet adhesion and clotting, are elevated in some migraine-with-aura patients both during and between attacks.

A separate structural observation adds another layer: women with migraine with aura have higher rates of patent foramen ovale (PFO), a small opening between the right and left atria of the heart that fails to close after birth. PFO is present in roughly 25 to 30 percent of the general population but appears more prevalent in those with migraine with aura, with some studies reporting rates above 40 percent in this group. The proposed mechanism is that small venous clots or vasoactive substances that would normally be filtered by the pulmonary circulation can cross through the PFO directly into the systemic arterial circulation and reach the brain. Whether closing the PFO in migraine patients alters their stroke risk remains an area of active investigation; current evidence does not support routine PFO closure for migraine, but the anatomical association adds texture to a risk that is otherwise understood mainly through epidemiology.

The endothelial dysfunction hypothesis provides yet another pathway. Migraine with aura is associated with subclinical abnormalities in endothelial function, the regulatory capacity of the cells lining blood vessels to modulate tone, permeability, and platelet interactions. These abnormalities, detectable by measurements of flow-mediated dilation, suggest that the vascular phenotype of migraine with aura is not confined to acute attacks but represents a persistent background state of altered vascular biology. This is consistent with the observation that the stroke risk elevation in migraine with aura persists between attacks, not only during or immediately after them.

Hormonal context is also relevant to the mechanism. Estrogen has real effects on coagulation: it increases hepatic production of certain clotting factors, including fibrinogen and factors VII and X, and decreases levels of protein S, a natural anticoagulant, shifting the balance toward a more procoagulant state. This is why estrogen-containing contraception raises the risk of venous thromboembolism in the general population and why, when combined with the migraine-with-aura phenotype and its own vascular abnormalities including platelet activation and possible PFO, the stroke risk amplifies in a way that is more than additive. The coagulation shift from exogenous estrogen adds a procoagulant layer to a vascular system that is already more prone to thrombotic events.

What the Evidence Shows

The epidemiological case for migraine with aura as a stroke risk factor in women is built on multiple converging datasets, not a single study. 4 / Promising

The Women’s Health Study, a landmark prospective cohort that enrolled nearly 40,000 female health professionals and followed them for a decade, found that women with active migraine with aura had roughly twice the risk of ischemic stroke compared to women without migraine. The absolute risk remained low in young, otherwise healthy women, but the relative increase was consistent and statistically robust. Women with migraine without aura did not show the same elevation, which established the aura distinction as the clinically meaningful separator.

A 2016 meta-analysis published in the British Medical Journal, drawing on data from more than 600,000 participants across multiple cohort studies, confirmed a relative risk of approximately 2.0 for ischemic stroke in people with migraine with aura compared to those without migraine. The association was stronger in women than in men, and stronger in younger age groups. The same analysis found that the combination of migraine with aura and oral contraceptive use raised the relative risk substantially higher, with some estimates exceeding six times the baseline for ischemic stroke, though absolute numbers for individual young women without other risk factors remained in a low range.

Research from Denmark, using national registry data to track millions of individuals over time, has consistently found that migraine with aura is associated with higher rates of ischemic stroke and that the risk is more pronounced in women during the reproductive years. A 2010 Danish study published in BMJ followed more than 35,000 women and found that those with migraine with aura had a nearly threefold increased rate of ischemic stroke compared to women without migraine. Danish data also suggests that women with migraine with aura have a modestly elevated risk of other cardiovascular events, including myocardial infarction and cardiovascular mortality, over longer follow-up periods, which is consistent with the hypothesis that an underlying vascular phenotype is driving the signal rather than the migraine headache itself.

Smoking compounds the risk through a separate and additive pathway involving oxidative damage to arterial endothelium and acceleration of atherosclerosis. The combination of migraine with aura, estrogen-containing contraception, and smoking has been estimated in some case-control studies to raise stroke risk by a factor approaching thirteen compared to women who have none of these three factors. Individual absolute risks still depend heavily on baseline cardiovascular health, but the multiplicative interaction is clinically important enough that current guidelines from the World Health Organization and the American College of Obstetricians and Gynecologists categorize migraine with aura as a contraindication to combined hormonal contraceptives, meaning the risks generally outweigh the benefits for most women in this combination.

The absolute risk perspective is essential alongside the relative risk numbers. A young woman with migraine with aura who does not smoke and does not use estrogen-containing contraception faces a real but still relatively low absolute risk of stroke in any given year. The compounding is where the clinical urgency emerges: each additional modifiable factor she carries shifts the absolute number meaningfully, and the modifiable factors are precisely where intervention is possible.

Beyond stroke, there is growing attention to the longer-term cardiovascular trajectory of women with migraine with aura. Data from Tobias Kurth and colleagues, drawing on Women’s Health Study follow-up, found that migraine with aura was associated with higher rates of major cardiovascular events across more than two decades of follow-up, including ischemic heart disease, not only stroke. This broader cardiovascular signal is less established than the stroke association, but it suggests that migraine with aura may be a marker of a systemic vascular phenotype that deserves attention beyond the acute stroke question.

Cardiologist's Note

The reason this matters clinically is compounding, and I want to be precise about where the practical information lives. Migraine with aura on its own modestly raises stroke risk, and the condition itself is not directly modifiable. But it compounds dangerously with two factors that are both modifiable: smoking and estrogen-containing contraception. That is where the most practically important guidance sits. A woman with migraine with aura is generally advised to avoid smoking and estrogen-containing contraception, because the combination raises stroke risk more than any one factor alone, and removing those two factors represents a real and achievable reduction in her compounded risk.

The first step, though, is even simpler than that, and it is often skipped. Many women have never been told which type of migraine they have. They know they get migraines; they may have been managing them for years with triptans or preventive medications. But the aura distinction, whether they experience visual disturbances, sensory symptoms, or other neurological phenomena before or during the headache, is the clinically meaningful separation for cardiovascular risk purposes, and it is not always asked about or documented in primary care or cardiology records. Before we can have the compounding conversation, we need to establish whether the aura is present. That question belongs in every primary care encounter for a woman reporting migraines.

What I see in practice is a persistent gap between the neurological framing and the cardiovascular framing of migraine. Migraines are managed as a pain and frequency problem, and that management is appropriate and important. But the cardiovascular risk dimension does not automatically surface in that context. A neurologist optimizing migraine prevention is not necessarily conducting a cardiovascular risk assessment. A cardiologist evaluating a woman for palpitations or hypertension may not think to ask about her migraine type. The result is that aura status, and the compounding risk it implies, can remain invisible in a woman’s clinical record for years. Ensuring it is documented in the cardiovascular context, not only the headache context, and factored into contraception and smoking conversations, is a straightforward fix with meaningful risk consequences.

I also want to name the pattern I see in women with migraine who have been dismissed. Headache is one of the presentations most associated with inadequate evaluation in women, who are more likely than men to have their pain attributed to anxiety or stress rather than investigated on its merits. The cardiovascular dimension of migraine with aura is another reason that dismissal carries real costs: it is not merely a comfort issue but a risk-factor conversation that has been deferred. A woman who knows her migraine type and its cardiovascular interactions is equipped to advocate for appropriate evaluation in a way that a woman who has only been told to manage her headaches is not.

Progestin-Only and Non-Hormonal Contraception: The Safer Alternatives for Women With Migraine With Aura

The contraception conversation in women with migraine with aura centers on one specific mechanism: the estrogen component in combined oral contraceptives. Combined hormonal contraceptives, which include estrogen and progestin together, carry an established thrombotic and vasoconstrictive risk that compounds with the vascular dysregulation underlying migraine with aura. The clinical concern is stroke, and the risk elevation is sufficient that the World Health Organization Medical Eligibility Criteria for Contraceptive Use (WHO MEC) classifies combined hormonal methods in women with migraine with aura as Category 4, meaning the risks are unacceptable and the method should not be used.

That restriction is specific to estrogen-containing methods. The progestin-only landscape carries a substantially different risk profile and offers practical contraceptive options for women who need highly effective pregnancy prevention.

Progestin-only pills, sometimes called the mini-pill, are classified as WHO MEC Category 2 in women with migraine with aura, meaning the advantages generally outweigh the theoretical or proven risks and the method can generally be used with clinical supervision. Progestin does not carry the estrogen-mediated thrombotic risk, does not induce the same vasoconstrictive effects, and does not appear to compound migraine-related cerebrovascular risk in the same way. The primary clinical consideration with progestin-only pills is strict adherence, as they have a narrower effective window than combined pills.

Levonorgestrel-releasing intrauterine devices (LNG-IUDs), including Mirena, Kyleena, and Liletta, are classified as WHO MEC Category 1 for women with migraine with aura: no restriction, meaning the method can be used without qualification. The progestin released by LNG-IUDs acts predominantly locally at the level of the uterine cavity. Systemic progestin absorption is low and does not produce the vascular effects relevant to stroke risk. LNG-IUDs also offer long-acting effectiveness for three to eight years without adherence dependence, which is a practical advantage in this clinical context.

The copper intrauterine device is similarly WHO MEC Category 1 for women with migraine with aura. It contains no hormonal component and therefore has no interaction with the cerebrovascular risk pathway. For women who prefer entirely non-hormonal contraception, the copper IUD is the most effective option in that category, with failure rates below 1 percent per year, comparable to tubal ligation.

Depot medroxyprogesterone acetate (DMPA) falls within WHO MEC Category 2 for migraine with aura. Some data suggest DMPA may transiently affect headache patterns in certain women, but the current evidence does not support a meaningful stroke risk elevation comparable to combined estrogen-containing methods.

The key clinical distinction is not between hormonal and non-hormonal contraception broadly, but between estrogen-containing and estrogen-free methods specifically. Progestin-only pills, hormonal IUDs, implants, and copper IUDs all remain available for women with migraine with aura. A clinician familiar with both the WHO MEC framework and the migraine-with-aura designation can identify an appropriate method without trading contraceptive effectiveness for vascular safety.

What to Do This Week

Find out whether your migraines include aura. Aura refers to the visual or neurological symptoms that occur before or during the headache: flickering lights, an expanding arc of bright zigzags, a temporary blind spot, tingling on one side of the face or body, or brief difficulty with words. These symptoms typically last 20 to 60 minutes and then resolve. If you are not sure whether what you experience qualifies as aura, describe your pre-headache experience to your clinician specifically and ask directly. The stroke association is specific to migraine with aura, not migraine without aura, so the distinction has real clinical meaning.
If you have migraine with aura, make sure it is formally noted in your medical record and visible in your cardiovascular risk assessment, not only in the neurology or headache section. It should be part of the picture your primary care clinician sees when making decisions about contraception, smoking counseling, and blood pressure management. If it is not in your chart in a way that is visible across specialties, ask to have it added.
If you use or are considering estrogen-containing contraception and you have migraine with aura, ask your clinician explicitly about this interaction. Progestin-only methods, including the progestin-only pill, hormonal IUDs, and implants, do not carry the same compounded stroke risk as estrogen-containing methods. Non-hormonal options are also available. The conversation about migraine type belongs in the contraception discussion, not as an afterthought.
Do not smoke, and if you currently smoke, treat cessation as a medical priority, not a lifestyle preference. For a woman with migraine with aura, smoking is not a background risk factor; it is a direct multiplier on a risk that is already elevated. The compounding data supports framing cessation assistance explicitly in this context with your clinician, including pharmacological support where appropriate.
Manage your other cardiovascular risk factors, particularly blood pressure. Hypertension compounds stroke risk independently of migraine, and the vascular effects of uncontrolled blood pressure interact with an already sensitized vascular system. If your blood pressure is elevated, treatment is also a stroke-prevention measure in the migraine-with-aura context and should be addressed with at least the same urgency as the migraine management itself.

Migraine with aura is a recognized stroke risk factor in women, most consequential where it compounds with smoking and estrogen-containing contraception. Knowing which kind of migraine a woman has, removing the modifiable factors it interacts with, and ensuring the diagnosis is visible across her clinical record is how a headache diagnosis becomes relevant cardiovascular information. The migraine itself may not be modifiable, but the risk it amplifies in combination with other factors very often is.

Find out which signals are active in your own pattern.

Take the Women's Signal Check

Did this land?

The conversation

Join the men working through this in the open.